InvestmentPitch Media Video Discusses Love Pharma's Appointment of Joshua Maurice as its Chief Operating Officer - Video Available on

Love Pharma Inc. (CSE: LUV), an international sexual health, wellness, and psychedelics company, has. Mr. Maurice brings 20 years of experience in consumer goods with a focus on the development of over-the-counter drug and nutraceuticals, including efficacy, clinical research, branding, marketing, advertising, and global retail distribution.

For more information, please view the InvestmentPitch Media "video" which provides additional information about this news. If this link is not enabled, please visit and enter "Love Pharma" in the search box.

He was most recently at Callitas Therapeutics where over 4 years he quickly rose through the ranks from Director of Sales & Marketing to VP of Sales & Business Development and then to President. Having successfully launched a number of retail brands from concept to distribution, both direct-to-consumer and with brick-and-mortar retailers including Walmart, CVS, Target, and Walgreens, Mr. Maurice's track record in streamlining manufacturing and supply chain management, while maximizing profitability and product performance should prove invaluable to Love Pharma.

Joshua Maurice, COO, stated: "While I am truly impressed by the breadth of the Love Pharma portfolio-ranging from CBD and psychedelics to sexual wellness and conception-it's being ideally positioned to bring novel health and wellness products to market that really excites me about joining the Love Pharma team; and I look forward to focusing on how our innovative technologies can legitimately improve the lives of our customers."

In his new role at Love Pharma, Mr. Maurice will be responsible for the following:

  • Overseeing day-to-day operations, including logistics and supply chain systems
  • Directing the acquisition of new technologies as well as product development
  • Steering the launch of new products, including key branded products such as BLOOM™ and AURALIEF™, and their respective marketing and advertising campaigns
  • Leading contract negotiations and vendor acquisitions

Zachary Stadnyk, CEO, added: "Joshua's expertise is exactly what we need to properly execute the rollout of new products as well as to oversee the distribution and marketing of our strong portfolio of therapeutic and pharmaceutical products. We welcome Joshua, a talented senior executive with years of experience, to the Love Pharma team, where his guidance and history will make him an invaluable asset; and we look forward to the future growth and expansion that he will lead."

Founded in 2020, Love Pharma is focused on the Global Sexual Health, Wellness, and Psychedelics markets, with a mission to bring to market innovative products that enhance sexual health and wellness while providing an improved quality of life. Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.

The company is initially launching Bloom, a topical gel that increases blood circulation and sensitivity, with future hemp-infused versions, designed to further improve blood circulation and sensitivity, along with Auralief, a discreet cannabis-infused oral strip that expedites and enhances the desired effects of THC and CBD. The company has a number of other proven products in the pipeline to aid in mental and sexual health and wellness. The company is also actively seeking additional mergers and acquisitions to complement its strong portfolio of intellectual property.

The shares which began trading on the CSE on September 30, are trading at $0.08. For more information, please visit the company's website, contact Zach Stadnyk, President and CEO, at 604-343-2977 or by email at

About InvestmentPitch Media

InvestmentPitch Media leverages the power of video, which together with its extensive distribution, positions a company's story ahead of the 1,000's of companies seeking awareness and funding from the financial community. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

InvestmentPitch Media
Barry Morgan, CFO

To view the source version of this press release, please visit

News Provided by Newsfile via QuoteMedia

The Conversation (0)
HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

HealthTab Supports Patient Testing in the First Rexall® Pharmacy Walk-In Clinic

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) ("Avricore Health" or the "Company") is expanding its innovative point-of-care chronic and infectious disease screening and health-data management platform, HealthTab™, further into the Canadian pharmacy ecosystem with one of Canada's largest pharmacy retailers, Rexall Pharmacy Group ULC ("Rexall").

"With Pharmacies' expanded scope and rising patient demand, the need for the clinical pharmacy practice is greater than ever," said Hector Bremner, CEO of Avricore Health. "We're excited to work with Rexall pharmacy teams to support positive patient outcomes through real-time insights into their health."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
doctor with hands together, palms up below digital medical symbols

Innovations and Opportunities in European Healthcare Technologies

In recent years, European companies have emerged as trailblazers in healthcare technology, effectively changing the face of health and patient care. Through innovation, they're not only improving systems, processes and patient outcomes but also saving lives.

These advanced European technologies are often only distributed and implemented exclusively within the European Union. The good news is that it doesn't need to stay this way.

Bringing European healthcare technologies to the North American market can potentially improve healthcare in this part of the world, open up new market opportunities for investors and expose those companies to significant growth capital.

Keep reading...Show less

Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution , 100 mg/mL due to Crystallization

Company Contact:
Novartis Pharmaceuticals Corporation

Novartis is conducting a voluntary nationwide recall at the consumer level of one lot of its Sandimmune ® Oral Solution (cyclosporine oral solution, USP), 100 mgmL in the US due to crystal formation observed in some bottles, which could potentially result in incorrect dosing. No other Sandimmune formulations are impacted.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health Corporate Update - Mid-Year Review Demonstrates Company on Right Track

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world.

"We've had an incredible year so far and we're very excited about what's still to come," said Hector Bremner, CEO of Avricore Health Inc. "Make no mistake, with new partners in Canada and expansion into the UK, we have nothing but blue sky in front of us."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics  to Existing Shareholders

BriaCell Receives Court Approval for the Share Arrangement Spinning Out BriaPro Therapeutics to Existing Shareholders

  • August 31, 2023 is the expected effective date for the distribution contemplated by the Arrangement.

briacell therapeutics corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announces that the Company has received court approval for the previously-announced plan of arrangement (the "Arrangement") pursuant to which certain pipeline assets of the Company, including Bria-TILsRx™ and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer (the "SpinCo Assets"), will be spun-out to BriaPro Therapeutics Corp. ("SpinCo"), resulting in a 23 owned subsidiary of the Company upon closing of the Arrangement with the remaining 13 held by BriaCell shareholders ("BriaCell Shareholders").

Subject to regulatory approvals, the Arrangement is expected to take place on or around August 31, 2023.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Principal Technologies (TSXV:PTEC)

Principal Technologies

Keep reading...Show less

Latest Press Releases

Related News